Search
image1
HomeProductsCompanyInvestorsNewsSupportContactblog
CellaVision AB: Resolutions from Annual General Meeting 2009
2009-04-27
English
The CellaVision Annual General Meeting (AGM) convened earlier today in Lund, April 27 2009, and resolved as follows:
Statement of Income and Balance Sheet for the parent company and the Group for the year 2008 was adopted. The AGM approved the Board of Directors' and CEO's proposal to carry forward the profits at the disposal of the Meeting of SEK 32,248,603.
 
The AGM discharged the members of the Board and the Chief Executive Officer from liability.
 
The AGM decided that the Board of Directors shall consist of five regular members and no alternatives. The ordinary Board Members Niels Freiesleben, Christer Fåhraeus, Lars Gatenbeck, Sven-Åke Henningsson and Torbjörn Kronander were re-elected and Lars Gatenbeck was elected Chaiman of the Board.
 
The AGM decided that the remuneration to the Chairman of the Board shall amount to SEK 140,000 (140,000). The remuneration to other directors shall amount to SEK 70,000 (70,000) each, in total to the Board SEK 420,000 (420,000). Remuneration to the auditors shall be paid on a current account basis.

The General Annual Meeting's complete decisions as accounted for above are available at the company address, Ideon Science Park in Lund, and are sent to those share holders who request it.
 
 
Lund April 27, 2009
 
CellaVision AB (publ)
Board of Directors
 
 
CEO Yvonne Mårtensson's address to the meeting is available at www.cellavision.com.
 
 
For more information, please contact:
Lars Gatenbeck, Chairman of the Board, CellaVision AB.
Tel: +46 70 535 44 44. E-mail: lars.gatenbeck@gzgroup.se
Yvonne Mårtensson, CEO, CellaVision AB.
Tel: +46 708 33 77 82. E-mail: yvonne.martensson@cellavision.com
 
 
About CellaVision
CellaVision AB develops, markets, and sells market leading image analysis based systems for routine analysis of blood and other body fluids. The company has a core competence in development of software and hardware for automatic image analysis of cells and cell changes for applications in health and medical care. The company develops and markets systems for automatic differentials of white blood cells and red morphology, and software for education and quality assurance of differentials. The company's associates have expertise in advanced imaging analysis, artificial intelligence, and automated microscopy.
 
The company headquarters are in Lund, Sweden. The company also has subsidiaries in Florida, USA, Toronto, Canada and Yokohama, Japan. For more information, visit www.cellavision.com.
 
CellaVision's share is listed on First North Premier at the OMX Stockholm Stock Exchange. The company's Certified Advisor is Remium AB.
Archive

2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2002